Wave Life Sciences

RNA Readouts And Clinical Milestones Will Broaden Treatment Horizons

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

23 Mar 25

Updated

10 Dec 25

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

23.1%

7D

-10.6%

Loading

1Y

23.1%

7D

-10.6%

You can edit this narrative until Dec 11 5:05 AM. Then, changes will post as Updates.

Author's Valuation

US$27.2139.1% undervalued

AnalystConsensusTarget Fair Value

Shared on 10 Dec 25

Fair value Increased 34%

WVE: Obesity RNA Editing Breakthrough Is Expected To Drive Future Upside

Analysts have raised their price target on Wave Life Sciences by about $7 per share, reflecting increased confidence in the companys validated RNA editing approach, its expanding obesity pipeline, and its insulated Huntington's disease program despite sector specific setbacks. Analyst Commentary Bullish analysts view recent sector developments as reinforcing Wave Life Sciences competitive positioning, particularly in RNA editing and obesity, and see room for further upside as the company executes on its clinical milestones.

Shared on 01 May 25

Fair value Increased 52%

Shared on 24 Apr 25

Fair value Decreased 38%

AnalystConsensusTarget has increased shares outstanding growth rate from 0.1% to 0.3%.

Shared on 17 Apr 25

Fair value Increased 5.32%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

Fair value Decreased 9.20%

Shared on 02 Apr 25

Fair value Decreased 2.01%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 26 Mar 25

Fair value Increased 12%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

AnalystConsensusTarget Fair Value

US$27.21

39.1% undervalued

Future estimation in

% p.a.

0

Decrease

Increase

Current revenue growth rate

35.57%

Pharma revenue growth rate

0.63%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

6.63%

Calculation

US$36.34m

Earnings '28

x

185.20x

PE Ratio '28

=

US$6.73b

Market Cap '28

US$6.73b

Market Cap '28

/

204.80m

No. shares '28

=

US$32.86

Share Price '28

US$32.86 Share Price '28

Discounted to 2025 @ 6.63% p.a.

=

US$27.11

Fair Value '25